Phase I study of radiotherapy (RT) & durvalumab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) & follicular lymphoma (FL): The RADD study

MLA

Wendi Lin, et al. “Phase I Study of Radiotherapy (RT) & Durvalumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) & Follicular Lymphoma (FL): The RADD Study.” Journal of Clinical Oncology, vol. 38, May 2020, p. TPS8075. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........8ffedb85ace7428dbe8348c1a302c5e4&authtype=sso&custid=ns315887.

APA

Wendi Lin, Geoffrey Chong, Tom Witkowski, Richard Khor, Laura Johnston, Kate Manos, Andrew M. Scott, Allison Barraclough, Michael MacManus, Rachel Koldej, Eliza A Hawkes, Jake Shortt, Colm Keane, Sze Ting Lee, Leonid Churilov, David Ritchie, & Jodie Palmer. (2020). Phase I study of radiotherapy (RT) & durvalumab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) & follicular lymphoma (FL): The RADD study. Journal of Clinical Oncology, 38, TPS8075.

Chicago

Wendi Lin, Geoffrey Chong, Tom Witkowski, Richard Khor, Laura Johnston, Kate Manos, Andrew M. Scott, et al. 2020. “Phase I Study of Radiotherapy (RT) & Durvalumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) & Follicular Lymphoma (FL): The RADD Study.” Journal of Clinical Oncology 38 (May): TPS8075. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........8ffedb85ace7428dbe8348c1a302c5e4&authtype=sso&custid=ns315887.